Lisata Therapeutics, Inc. company information, Employees & Contact Information

Oct 20: Lisata Therapeutics to present at LD Micro Main Event in San Diego, 10:30 a.m. PT Stock Titan

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial GlobeNewswire

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development Yahoo Finance

$10M+ Milestones: Lisata Licenses Certepetide to Catalent for SMARTag® ADC Development Stock Titan

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference The Manila Times

Clinical-Stage Pharma Lisata Therapeutics Showcases Advanced Tumor Therapies at Major Investment Conference Stock Titan

Lisata Therapeutics and WARPNINE Announce iLSTA Trial GlobeNewswire

70% Partial Response Rate: Lisata's New Pancreatic Cancer Drug Shows Promise in Phase 1/2 Trial Stock Titan

Breakthrough Pancreatic Cancer Trial Achieves 100% Disease Control Rate with Novel Drug Combination Stock Titan

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer GlobeNewswire

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

Lisata Therapeutics and WARPNINE Announce Encouraging GlobeNewswire

Lisata Therapeutics and GATC Health Consummate First Step GlobeNewswire

Lisata Therapeutics Reports Encouraging Preliminary Cohort GlobeNewswire

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference GlobeNewswire

Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging GlobeNewswire

FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma OncLive

Lisata Therapeutics Partners with Catalent on ADC Technology Yahoo Finance

Lisata completes subject enrolment in multi-cancer trial of certepetide Clinical Trials Arena

CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug Fierce Biotech

Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ... Yahoo Finance

Lisata collaborates with GATC Health on drug development Pharmaceutical Technology

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Invest In Growth? Yahoo Finance

Dr. Erkki Ruoslahti Retires from Lisata Therapeutics Board of Directors citybiz

FDA Grants Orphan Drug Designation to LSTA1 in Osteosarcoma OncLive

Lisata Therapeutics stock price target raised to $32 from $20 at Brookline Investing.com

Endometriosis Treatment Market Size to Hit USD 5.74 Billion by 2034 Precedence Research

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics GlobeNewswire

Lisata Therapeutics inks global product license deal with Catalent Proactive financial news

Lisata Therapeutics reveals 'encouraging' preliminary data from pancreatic cancer treatment trial Proactive financial news

Lisata to present at LD Micro Main Event XIX Conference Proactive financial news

Lisata’s Autologous T Cell Therapy Is Safe but Fails to Slow T1D Disease Progression, Trial Finds BioSpace

Lisata announces preclinical research agreement to study certepetide with bevacizumab for endometriosis BioWorld MedTech

2 become 1: Caladrius and Cend merge into tumor-focused Lisata Therapeutics Fierce Biotech

LSTA Stock Price and Chart — NASDAQ:LSTA TradingView

Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedical GlobeNewswire

Progenitor Cell Therapy, a NeoStem Company, Invited to Present at Two Conferences in September GlobeNewswire